ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. It advances two lead clinical programs: rinzimetostat (ORIC-944), an allosteric EED/PRC2 inhibitor in Phase 1b trials for metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR exon 20 and atypical mutation inhibitor in Phase 1b trials for NSCLC. The company leverages expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies.
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001193125-26-064005 | EDGAR | 99K words |
| 2025-02-18 | 2024-12-31 | 0000950170-25-022273 | EDGAR | 95K words |
| 2024-03-11 | 2023-12-31 | 0000950170-24-029298 | EDGAR | 95K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008483 | EDGAR | 92K words |
| 2022-03-21 | 2021-12-31 | 0000950170-22-004239 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001564590-21-014865 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-03 | 2026-06-30 | 0001193125-26-330631 | EDGAR | 66K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280234 | EDGAR | 66K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107359 | EDGAR | 66K words |
| 2025-05-05 | 2025-03-31 | 0000950170-25-063564 | EDGAR | 62K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125471 | EDGAR | 63K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095467 | EDGAR | 63K words |
| 2024-05-06 | 2024-03-31 | 0000950170-24-053582 | EDGAR | 60K words |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059415 | EDGAR | 62K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041362 | EDGAR | 62K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018839 | EDGAR | 60K words |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022631 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016894 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-03 | 0001193125-26-330568 | EDGAR | 2K words |
| 2026-07-30 | 0001193125-26-326309 | EDGAR | 10K words |
| 2026-03-31 | 0001193125-26-134618 | EDGAR | 7K words |
| 2026-02-23 | 0001193125-26-064291 | EDGAR | 1K words |
| 2026-02-23 | 0001193125-26-063974 | EDGAR | 2K words |
| 2025-12-08 | 0001193125-25-310472 | EDGAR | 7K words |
| 2025-11-13 | 0001193125-25-280247 | EDGAR | 3K words |
| 2025-11-13 | 0001193125-25-280196 | EDGAR | 3K words |
| 2025-08-12 | 0000950170-25-107313 | EDGAR | 3K words |
| 2025-06-13 | 0001193125-25-140725 | EDGAR | 1K words |
102 total filings indexed. 74 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001796280 |
| Ticker | ORIC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.oricpharma.com |
| Listed | 2020-04-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ORIC (~200 tokens, structured JSON with cryptographic provenance)